Use of multiple biomarkers in heart failure

被引：10

作者：

Allen L.A. ^{[1
]}

机构：

[1] Division of Cardiology, Section of Heart Failure Cardiac Transplantation, University of Colorado Denver, Aurora, CO 80045

来源：

Current Cardiology Reports | 2010年 / 12卷 / 3期

关键词：

Biomarkers; Diagnosis; Heart failure; Multimarker; Prognosis; Risk prediction; Screening; Statistical models;

D O I：

10.1007/s11886-010-0109-6

中图分类号：

学科分类号：

摘要：

Biomarkers are becoming increasingly available for clinical use, particularly in the care of patients with heart failure. For health care providers, a major difficulty is how to interpret and apply these increasing amounts of diagnostic and prognostic information. Consequently, the scientific challenge is evolving from the discovery of biomarkers to the selection and validation of select panels of clinically useful markers that balance performance and practicality. Optimal combinations of biomarkers will vary based on the intended use (eg, diagnosis vs prognosis). The final goal must be to generate more actionable knowledge that improves patient management and outcomes, rather than merely creating greater complexity. Here we conceptually define multiple biomarker strategies, provide examples of emerging biomarker panels used in the care of patients with heart failure, and address key statistical and clinical issues for this rapidly evolving field. © Springer Science+Business Media, LLC 2010.

引用

页码：230 / 236

页数：6

共 45 条

[1] Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework, Clin Pharmacol Ther, 69, pp. 89-95, (2001)
[2] Vasan R.S., Biomarkers of cardiovascular disease: Molecular basis and practical considerations, Circulation, 113, pp. 2335-2362, (2006)
[3] Mark D.B., Felker G.M., B-type natriuretic peptide - A biomarker for all seasons?, N Engl J Med, 350, pp. 718-720, (2004)
[4] Allen L.A., Hernandez A.F., O'Connor C.M., Et al., End points for clinical trials in acute heart failure syndromes, J Am Coll Cardiol, 53, pp. 2248-2258, (2009)
[5] Donahue M.P., Marchuk D.A., Rockman H.A., Redefining heart failure: The utility of genomics, J Am Coll Cardiol, 48, pp. 1289-1298, (2006)
[6] Arab S., Gramolini A.O., Ping P., Et al., Cardiovascular proteomics: Tools to develop novel biomarkers and potential applications, J Am Coll Cardiol, 48, pp. 1733-1741, (2006)
[7] Hlatky M.A., Greenland P., Arnett D.K., Et al., Criteria for evaluation of novel markers of cardiovascular risk: A scientific statement from the American heart association, Circulation, 119, pp. 2408-2416, (2009)
[8] McGeechan K., Macaskill P., Irwig L., Et al., Assessing new biomarkers and predictive models for use in clinical practice: A clinician's guide, Arch Intern Med, 168, pp. 2304-2310, (2008)
[9] Braunwald E: Biomarkers in heart failure, N Engl J Med, 358, pp. 2148-2159, (2008)
[10] Lainscak M., Anker M.S., Von Haehling S., Et al., Biomarkers for chronic heart failure : Diagnostic, prognostic, and therapeutic challenges, Herz, 34, pp. 589-593, (2009)

← 1 2 3 4 5 →